中医药干预糖尿病视网膜病变的证据图谱分析

Evidence mapping of traditional Chinese medicine intervention in diabetic retinopathy

通过对中医药干预糖尿病视网膜病变的系统评价/Meta分析相关文献的证据进行分析,探索并呈现中医药干预糖尿病视网膜病变的证据质量。通过检索中国知网(CNKI)、万方(Wanfang)、维普(VIP)、中国生物医学文献服务系统(SinoMed)、PubMed、Web of Science、EMbase、Cochrane Library数据库,从建库至2023年11月发表的中医药干预糖尿病视网膜病变的系统评价/Meta分析。采用AMSTAR2量表对纳入文献进行方法学质量评价,并采用证据图谱综合呈现干预措施、系统评价/Meta分析纳入文献量、研究结论及方法学质量评价结果等信息。最终纳入51篇文献,干预措施中中药治疗占比较大,其次为中成药;治疗方法集中在补益法、活血法及化瘀法等。根据AMSTAR2量表评价结果显示,纳入文献基金资助信息、排除文献清单及前期研究方案等条目的阐述较差。证据图谱显示,中医药干预糖尿病视网膜病变有一定疗效,纳入文献中48篇结论为有益,2篇结论为可能有益,1篇为不清楚。总之,中医药干预糖尿病视网膜病变的相关研究证据质量整体为中等偏低,建议今后开展更高质量的相关研究以提供循证参考依据。

This study aims to assess the quality of evidence for the treatment of diabetic retinopathy with traditional Chinese medicine based on the systematic reviews/Meta-analyses of relevant studies.CNKI,Wanfang,VIP,SinoMed,PubMed,Web of Science,EMbase,and Cochrane Library were searched for the systematic reviews/Meta-analyses of traditional Chinese medicine interventions in diabetic retinopathy published from the inception to November 2023.A Measurement Tool to Assess Systematic Reviews 2(AMSTAR2)scale was used to assess the methodological quality of the included studies.An evidence map was built to present the information on intervention measures,the number of studies included in the systematic reviews/Meta-analyses,research conclusions,and methodological quality assessment results.A total of 51 studies were included.Traditional Chinese medicine interventions accounted for a large proportion of the intervention measures,followed by Chinese patent medicines.The treatment methods mainly included tonifying deficiency,activating blood,and resolving stasis.According to the AMSTAR2 scale assessment results,the descriptions of funding information for included studies,lists of excluded articles,and preliminary research protocols were particularly lacking.The evidence map showed that 48,2,and 1 studies concluded with beneficial effects,possible beneficial effects,and unclear effects,respectively.On the whole,traditional Chinese medicine demonstrated definite efficacy in the treatment of diabetic retinopathy,while the evidence pre-sents moderate to low quality.It is suggested that higher-quality studies remain to be carried out to provide more evidence.